RESUMEN
Antiangiogenesis therapy is one of the most common anticancer therapies. Bevacizumab is a monoclonal antibody that blocks the binding of the vascular endothelial growth factor to its high-affinity receptors. It is the only antiangiogenic agent approved for the first-line treatment of advanced non-small cell lung cancer (NSCLC). Many recent studies have attempted to determine the suit-able partners of bevacizumab in first-line treatment of NSCLC and evaluate its efficacy and safety as a second-line or beyond and con-tinuous treatment of beyond disease progression in patients with advanced NSCLC. This review summarizes current clinical research about the efficacy and safety of bevacizumab in the treatment of advanced NSCLC.
RESUMEN
Objective To evaluate the clinical effect of intense pulsed light(IPL) on infantile superficial strawberry hemangioma in proliferative phase.Methods 68 patients,with age range from 1 day to 24 months,received IPL therapy with a proper energy and intervals.The therapeutic effects of the patients were evaluated through comparison of the photographs before and after treatment.Results AII patients with IPL therapy had a general effective rate of 76.47%.Few patients had adverse effects such as burned vesicle, hyperpigmentation,etc.Conclusion The intense pulsed light can be used as an earlier therapeutic scheme for infantile superficial strawberry hemangioma in proliferative phase.